Results 131 to 140 of about 8,866 (177)

Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. [PDF]

Vet Dermatol, 2020
Goodale EC, White SD, Bizikova P, Borjesson D, Murrell DF, Bisconte A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, Jordan TJM, Emery CB, Outerbridge CA.   +13 more
europepmc   +1 more source

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia [PDF]

, 2015
Aymerich, Marta, Campo, Elías, Colomer, Dolors, Lagisetti, Chandraiah, López Guerra, Mónica, López Otín, Carlos, Montraveta, Arnau, Rodríguez, Vanina, Roldán, Jocabed, Rosich, Laia, Villamor Casas, Neus, Webb, Thomas R., Xargay-Torrent, Sçilvia   +12 more
core   +1 more source

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor. [PDF]

Int J Mol Sci, 2020
Lee KW, Lee WH, Han BS, Lee JH, Doo EK, Kim JH.   +5 more
europepmc   +1 more source

Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. [PDF]

Neuro Oncol, 2021
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R.   +12 more
europepmc   +1 more source

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]

, 2018
Bartlett, Nancy L.
core   +1 more source

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma [PDF]

, 2017

core   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. [PDF]

Int J Mol Sci
Zhao Y, Chakraborty P, Tomassetti J, Subha T, Massé S, Thavendiranathan P, Billia F, Lai PFH, Abdel-Qadir H, Nanthakumar K.   +9 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification. [PDF]

Oncotarget
Patel JN, Singh J, Ghosh N.
europepmc   +1 more source